News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Stem Cell Time Bombs Cause Leukaemia Relapse
Leukaemia “stem cells” can lie dormant in the body for a decade or more after a child achieves remission before being reactivated and causing a relapse, a new study shows.
Simple Blood Test Could Speed up Cancer Drug Development
Cancer drug development could accelerate in the future thanks to a simple and quick blood test that can help reveal the effectiveness of a new treatment, according to research presented this week at the ASCO annual meeting in Chicago.
New ‘Smart’ Pill Shown to Extend Lives of Patients with Most Aggressive Skin Cancer
The Institute of Cancer Research (ICR) was responsible for key research on the BRAF gene, which paved the way for the development of this first-of-its-kind personalised treatment for advanced melanoma.
ICR Scientist to Receive £2.14m Share of Inaugural Wellcome Trust Investigator Awards
Professor Dale Wigley of The Institute of Cancer Research (ICR) has been announced as a recipient of one of the inaugural Wellcome Trust Investigator Awards.
Gene Test Predicts Leukaemia Survival
Scientists at The Institute of Cancer Research (ICR) have found that a genetic test can be used to identify patients with the most common type of adult leukaemia who will not respond well to currently available drugs and should instead be considered for experimental treatments.
Girls’ Ages at First Period Getting Younger, Particularly Those From Poorer Backgrounds
Girls from poorer backgrounds are more likely to start their periods at a younger age, potentially putting them at a higher risk of breast cancer, according to a collaboration between the ICR and Breakthrough Breast Cancer.
Prostate Cancer Drug Developers Win Royal Society of Chemistry Award
A team of scientists at the ICR has won a prestigious Royal Society of Chemistry (RSC) award for the discovery and clinical development of prostate cancer drug abiraterone.
A new way to treat prostate cancer: The story of abiraterone
Abiraterone was designed and developed at The Institute of Cancer Research (ICR) and The Royal Marsden Hospital. First synthesised in the early 1990s, this year it completed the journey from an idea to life-extending treatment for men with advanced prostate cancer. The US Food and Drug administration (FDA) approved the use of abiraterone in men with castration resistant prostate cancer in April 2011, and European approval followed in September 2011.
Testing new radiotherapy techniques for breast cancer
Radiotherapy is one of the key treatments for cancer. More than 120,000 cancer patients in the UK are treated with radiotherapy each year and it continues to cure more people than all existing drugs combined. The Institute of Cancer Research founded its department of radiotherapy in the early 1940s and has been at the forefront of a number of important developments that have improved patient care.
New Type of Hormone Therapy Extends Prostate Cancer Patients’ Lives, Study Finds
The drug abiraterone acetate gave men with advanced prostate cancer an average of four months of extra life, according to Phase III trial results published in the New England Journal of Medicine today.
New type of hormone therapy extends prostate cancer patients’ lives
The drug abiraterone acetate gave men with advanced prostate cancer an average of four months of extra life, according to Phase III trial results published in the New England Journal of Medicine today.
World’s Biggest Medical Imaging Microchip Heralds Better Treatment for Cancer Patients
A collaboration between scientists at four UK organisations including The Institute of Cancer Research (ICR) has created the world’s biggest microchip designed for medical imaging.
